Compare AXP & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXP | MRK |
|---|---|---|
| Founded | 1850 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.1B | 260.2B |
| IPO Year | N/A | N/A |
| Metric | AXP | MRK |
|---|---|---|
| Price | $383.83 | $106.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 15 |
| Target Price | ★ $329.95 | $111.93 |
| AVG Volume (30 Days) | 2.5M | ★ 15.7M |
| Earning Date | 01-30-2026 | 02-03-2026 |
| Dividend Yield | 0.86% | ★ 3.24% |
| EPS Growth | 9.59 | ★ 58.08 |
| EPS | ★ 14.88 | 7.56 |
| Revenue | ★ $65,294,000,000.00 | $64,235,000,000.00 |
| Revenue This Year | $19.86 | $1.97 |
| Revenue Next Year | $8.91 | $4.96 |
| P/E Ratio | $25.69 | ★ $13.90 |
| Revenue Growth | ★ 10.22 | 1.68 |
| 52 Week Low | $220.43 | $73.31 |
| 52 Week High | $387.49 | $105.84 |
| Indicator | AXP | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 63.82 | 70.45 |
| Support Level | $372.77 | $96.79 |
| Resistance Level | $387.49 | $100.94 |
| Average True Range (ATR) | 7.27 | 2.47 |
| MACD | 0.23 | 0.24 |
| Stochastic Oscillator | 83.22 | 95.96 |
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. It operates in four segments: US consumer services, US commercial services, international card services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).